Characterization of an anti-fetal AChR monoclonal antibody isolated from a myasthenia gravis patient

Characterization of an anti-fetal AChR monoclonal antibody isolated from a myasthenia gravis patient

We report here the sequence and functional characterization of a recombinantly expressed autoantibody (mAb 131) previously isolated from a myasthenia gravis patient by immortalization of thymic B cells using Epstein-Barr virus and TLR9 activation. The antibody is characterized by a high degree of so...

Full description

Bibliographic Details
Main Authors:	Saxena, A, Stevens, J, Cetin, H, Koneczny, I, Webster, R, Lazaridis, K, Tzartos, S, Vrolix, K, Nogales-Gadea, G, Machiels, B, Molenaar, P, Damoiseaux, J, De Baets, M, Simon-Keller, K, Marx, A, Vincent, A, Losen, M, Martinez-Martinez, P
Format:	Journal article
Language:	English
Published:	Springer Nature 2017

Similar Items

Antibodies to AChRs in seronegative myasthenia gravis
by: Leite, M, et al.
Published: (2006)

Direct proof of the in vivo pathogenic role of the AChR autoantibodies from myasthenia gravis patients.
by: Gregory Kordas, et al.
Published: (2014-01-01)

Differential Cytokine Changes in Patients with Myasthenia Gravis with Antibodies against AChR and MuSK.
by: Vuslat Yilmaz, et al.
Published: (2015-01-01)

Preferential expression of AChR epsilon-subunit in thymomas from patients with myasthenia gravis.
by: Maclennan, C, et al.
Published: (2008)

Effect of sera from AChR-antibody negative myasthenia gravis patients on AChR and MuSK in cell cultures.
by: Farrugia, M, et al.
Published: (2007)

Nomogram for short-term outcome assessment in AChR subtype generalized myasthenia gravis
by: Rui Zhao, et al.
Published: (2021-06-01)

Myasthenia gravis in a woman with congenital AChR deficiency due to epsilon-subunit mutations.
by: Croxen, R, et al.
Published: (2002)

Compromised fidelity of B-cell tolerance checkpoints in AChR and MuSK myasthenia gravis
by: Lee, J, et al.
Published: (2016)

A Stable Cell Line Expressing Clustered AChR: A Novel Cell-Based Assay for Anti-AChR Antibody Detection in Myasthenia Gravis
by: Yu Cai, et al.
Published: (2021-07-01)

The clinical outcome in AChR-positive generalized myasthenia gravis: A retrospective observational study
by: Pawan T Ojha, et al.
Published: (2023-01-01)

Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis.
by: Deymeer, F, et al.
Published: (2007)

The association of PTPN22 R620W polymorphism is stronger with late-onset AChR-myasthenia gravis in Turkey.
by: Gizem A Kaya, et al.
Published: (2014-01-01)

Impact of COVID-19 in AChR Myasthenia Gravis and the Safety of Vaccines: Data from an Italian Cohort
by: Antonino Lupica, et al.
Published: (2022-04-01)

Correction: Direct Proof of the In Vivo Pathogenic Role of the AChR Autoantibodies from Myasthenia Gravis Patients.
by: PLOS ONE Staff
Published: (2015-01-01)

Correction: direct proof of the in vivo pathogenic role of the AChR autoantibodies from myasthenia gravis patients.
by: PLOS ONE Staff
Published: (2015-01-01)

Oral Microbiota Profile in a Group of Anti-AChR Antibody–Positive Myasthenia Gravis Patients
by: Chao Huang, et al.
Published: (2022-07-01)

Consensus recommendation for the treatment of generalised Myasthenia Gravis with anti-acetylcholine receptor antibodies (gMG AChR+) in Spain
by: Elena Cortés-Vicente, et al.
Published: (2025-01-01)

Autoantibody of NRIP, a novel AChR‐interacting protein, plays a detrimental role in myasthenia gravis
by: Li‐Kai Tsai, et al.
Published: (2021-06-01)

Clinical outcomes in AchR antibody-positive myasthenia gravis: Where does rituximab stand in the current times?
by: Megha Chetan Dhamne
Published: (2023-01-01)

A retrospective multicenter study on clinical and serological parameters in patients with MuSK myasthenia gravis with and without general immunosuppression
by: Koneczny, I, et al.
Published: (2024)

Short-term and long-term prognoses in AChR-Ab positive very-late-onset myasthenia gravis patients
by: Nairong Xie, et al.
Published: (2025-01-01)

AChR phosphorylation and indirect inhibition of AChR function in seronegative MG.
by: Plested, C, et al.
Published: (2002)

Clinical Characteristics and Prognosis of Anti-AChR Positive Myasthenia Gravis Combined With Anti-LRP4 or Anti-Titin Antibody
by: Yuping Chen, et al.
Published: (2022-05-01)

A retrospective multicenter study on clinical and serological parameters in patients with MuSK myasthenia gravis with and without general immunosuppression
by: Inga Koneczny, et al.
Published: (2024-04-01)

Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics
by: Konstantinos Lazaridis, et al.
Published: (2020-02-01)

Correlation between polymorphisms in the AChR gamma and delta subunit promoters and clinical phenotype in AChR deficiency patients
by: Bonifati, D, et al.
Published: (2004)

Discovery of functionally distinct anti-C7 monoclonal antibodies and stratification of anti-nicotinic AChR positive Myasthenia Gravis patients
by: Eleonora Lekova, et al.
Published: (2022-09-01)

Practical Management for Use of Eculizumab in the Treatment of Severe, Refractory, Non-Thymomatous, AChR + Generalized Myasthenia Gravis: A Systematic Review
by: Waheed W, et al.
Published: (2022-07-01)

Juvenile Generalized Myasthenia Gravis With AChR and MuSK Antibody Double Positivity: A Case Report With a Review of the Literature
by: XiuShan Ge, et al.
Published: (2022-05-01)

FoxP3− Tr1 Cell in Generalized Myasthenia Gravis and Its Relationship With the Anti-AChR Antibody and Immunomodulatory Cytokines
by: Huanyu Meng, et al.
Published: (2021-12-01)

MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters
by: Koneczny, I, et al.
Published: (2013)

MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters.
by: Koneczny, I, et al.
Published: (2013)

Gut microbiota-derived butyrate restores impaired regulatory T cells in patients with AChR myasthenia gravis via mTOR-mediated autophagy
by: Long He, et al.
Published: (2024-04-01)

Therapeutic Plasma Exchange in AChR-Ab Positive Generalized Myasthenia Gravis: A Real World Study About Its Early Response
by: Chen J, et al.
Published: (2024-04-01)

Practical Management for Use of Eculizumab in the Treatment of Severe, Refractory, Non-Thymomatous, AChR + Generalized Myasthenia Gravis: A Systematic Review [Erratum]
by: Waheed W, et al.
Published: (2022-08-01)

Overexpression of rapsyn in rat muscle increases acetylcholine receptor levels in chronic experimental autoimmune myasthenia gravis.
by: Martínez-Martínez, P, et al.
Published: (2007)

MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters.
by: Inga Koneczny, et al.
Published: (2013-01-01)

ACHR-positive generalized myasthenia gravis: The old is gold and the new is for us to explore
by: Fu Liong Hiew
Published: (2023-01-01)

Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis.
by: Losen, M, et al.
Published: (2005)

Increased serum IL-2, IL-4, IL-5 and IL-12p70 levels in AChR subtype generalized myasthenia gravis
by: Xiao Huan, et al.
Published: (2022-05-01)